Your browser doesn't support javascript.
loading
Efficacy and Safety of Adalimumab in Patients with Behçet Uveitis: A Systematic Review and Meta-Analysis.
Sener, Hidayet; Evereklioglu, Cem; Horozoglu, Fatih; Gunay Sener, Ayse Busra.
Afiliación
  • Sener H; Department of Ophthalmology, Division of Uvea-Behçet Unit, Erciyes University Medical Faculty, Kayseri, Turkey.
  • Evereklioglu C; Department of Ophthalmology, Division of Uvea-Behçet Unit, Erciyes University Medical Faculty, Kayseri, Turkey.
  • Horozoglu F; Department of Ophthalmology, Division of Uvea-Behçet Unit, Erciyes University Medical Faculty, Kayseri, Turkey.
  • Gunay Sener AB; Department of Medical Informatics and Biostatistics, Erciyes University Medical Faculty, Kayseri, Turkey.
Ocul Immunol Inflamm ; 32(1): 89-97, 2024 Jan.
Article en En | MEDLINE | ID: mdl-36625549
PURPOSE: To examine the long-term efficacy and safety of adalimumab (ADA) in patients with Behçet uveitis (BU). METHODS: A systematic review and meta-analysis of observational studies was performed. Pooled results are presented as mean difference or standardized mean difference (std diff) and 95% confidence intervals (CI). Visual acuity (VA), intraocular inflammation grade, central macular thickness, corticosteroid (CS) sparing effect and adverse events were evaluated. RESULTS: Ten studies were included finally for quantitative and qualitative synthesis. ADA therapy resulted in 0.124 (95%CI: 0.084, 0.165) logMAR improvement in VA. In addition, ADA therapy resulted in decreased grade of intraocular inflammation [std diff, -1.187 (95%CI: -1.508, -0.866)] and macular thickness [std diff, -0.564 (95%CI: -0.843, -0.286)] and caused a decrease in CS dosage [std diff, -1.809 (95%CI: -2.420, -1.198)]. The pooled rate of overall adverse events for ADA in 301 patients was 8.5% (95%CI: 0.039, 0.177). CONCLUSION: ADA is an efficient therapy that improves VA and controls intraocular inflammation, macular edema and retinal vasculitis. As the disease exposure time increased, improvement in VA was less. The safety and CS-sparing effect of ADA were demonstrated with few adverse effects. The results provided evidence that ADA can be used safely and efficiently as the first-line drug in patients with BU.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis / Síndrome de Behçet / Vasculitis Retiniana Tipo de estudio: Observational_studies / Qualitative_research / Systematic_reviews Límite: Humans Idioma: En Revista: Ocul Immunol Inflamm Asunto de la revista: ALERGIA E IMUNOLOGIA / OFTALMOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis / Síndrome de Behçet / Vasculitis Retiniana Tipo de estudio: Observational_studies / Qualitative_research / Systematic_reviews Límite: Humans Idioma: En Revista: Ocul Immunol Inflamm Asunto de la revista: ALERGIA E IMUNOLOGIA / OFTALMOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido